Louis Garguilo
ARTICLES BY LOUIS
-
2/3/2020
We may think we’ve been through this before with other coronaviruses such as SARS and MERS … but this time it feels different, like a larger confluence of too many overlapping and unstable tectonic plates.
-
2/3/2020
Still today one of the least explored dimensions of drug development and manufacturing outsourcing is the “no-choice partnership.” This might be an inherited relationship, or when unique platforms, technologies, and therapies leave few CDMOs that can actually assist. We did more exploring for you.
-
1/29/2020
Among the digital technologies that biopharma organizations can target for investment, the first choice is cyber security. But is enough of that investment steered to supply chains? And what of cyber security at CDMOs? Here’s a detailed analysis.
-
1/23/2020
Michael Mulkerrin, VP, Head of CMC, ADC Therapeutics, has been a part of the biopharma industry for 35 years, the first 16 at Genentech. He’s a member of the Council of Experts, United States Pharmacopeia (USP). Recently, he offered some sage advice regarding CDMO relationships.
-
1/15/2020
What equipment is essential at the CDMO assisting with your cell and gene therapy development and production? I’ve received some details via an investigation into Harvard’s Center for Advanced Biological Innovation and Manufacturing, and a discussion with the CEO & President of GE Healthcare Life Sciences.
-
1/13/2020
Bottlenecks and backlogs in development and production of cell and gene therapies. Harvard to the rescue. Actually, Harvard with partners, such as companies familiar to Outsourced Pharma readers. But what will go into the the $50 million Center for Advanced Biological Innovation and Manufacturing? We’ve got exclusive details.
-
1/6/2020
Stanley Crooke, M.D., Ph.D., founder, chairman, and CEO, Ionis Pharmaceuticals, proclaims: “Biotech has done a wonderful job of convincing Big Pharma to outsource.” James Mackay, Ph.D., founder, president, and CEO, Aristea Therapeutics, says: "Don’t call CDMOs 'service providers.'” Both CEOs are focused on biotech productivity.
-
12/30/2019
Welcome to the melodious-sounding “Twenty-Twenties.” What correspondingly pleasant harmonies will we hear from our drug industry during the second decade of this millennium? James Mackay, Ph.D., founder, president, and CEO, Aristea Therapeutics, and Stanley Crooke, M.D., Ph.D., founder, chairman, and CEO, Ionis Pharmaceuticals, predict a virtuosity emanating from the halls of biotech.
-
12/11/2019
It appears we never grow too old for a visit from the North Pole. “So, Louis,” a well-rounded Santa Claus in red dress and cheeks says through an unsettling wry smile. “Has your drug development and manufacturing outsourcing sector been good this year?” Here’s how I replied …
-
12/3/2019
“We're keen to get complete access, and full visibility, to our supply chain. This will in fact give us that desired end-to-end supply-chain transparency. It will improve the quality of so many of our decisions,” says Barry Moore, Head of Clinical Supply Chain Solutions for GSK, and Chairman of the Clinical Supply Blockchain Working Group (CSBWG)